179 related articles for article (PubMed ID: 34112707)
1. Sulindac, a Nonselective NSAID, Reduces Breast Density in Postmenopausal Women with Breast Cancer Treated with Aromatase Inhibitors.
Thompson PA; Huang C; Yang J; Wertheim BC; Roe D; Zhang X; Ding J; Chalasani P; Preece C; Martinez J; Chow HS; Stopeck AT
Clin Cancer Res; 2021 Oct; 27(20):5660-5668. PubMed ID: 34112707
[TBL] [Abstract][Full Text] [Related]
2. Sulindac Improves Stiffness and Quality of Life in Women Taking Aromatase Inhibitors for Breast Cancer.
Martinez JA; Wertheim BC; Roe DJ; Chalasani P; Cohen J; Baer L; Chow HS; Stopeck AT; Thompson PA
Breast Cancer Res Treat; 2022 Feb; 192(1):113-122. PubMed ID: 35039952
[TBL] [Abstract][Full Text] [Related]
3. Changes in breast density and circulating estrogens in postmenopausal women receiving adjuvant anastrozole.
Prowell TM; Blackford AL; Byrne C; Khouri NF; Dowsett M; Folkerd E; Tarpinian KS; Powers PP; Wright LA; Donehower MG; Jeter SC; Armstrong DK; Emens LA; Fetting JH; Wolff AC; Garrett-Mayer E; Skaar TC; Davidson NE; Stearns V
Cancer Prev Res (Phila); 2011 Dec; 4(12):1993-2001. PubMed ID: 21885816
[TBL] [Abstract][Full Text] [Related]
4. Relationship Between Breast Density and Selective Estrogen-Receptor Modulators, Aromatase Inhibitors, Physical Activity, and Diet: A Systematic Review.
Ekpo EU; Brennan PC; Mello-Thoms C; McEntee MF
Integr Cancer Ther; 2016 Jun; 15(2):127-44. PubMed ID: 27130722
[TBL] [Abstract][Full Text] [Related]
5. Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial.
Goss PE; Hershman DL; Cheung AM; Ingle JN; Khosla S; Stearns V; Chalchal H; Rowland K; Muss HB; Linden HM; Scher J; Pritchard KI; Elliott CR; Badovinac-Crnjevic T; St Louis J; Chapman JA; Shepherd LE
Lancet Oncol; 2014 Apr; 15(4):474-82. PubMed ID: 24636210
[TBL] [Abstract][Full Text] [Related]
6. Bone metabolism and quality-of-life of postmenopausal women with invasive breast cancer receiving neoadjuvant hormonal therapy: sub-analyses from celecoxib anti-aromatase neoadjuvant (CAAN) trial.
Chow LW; Yip AY; Chu WP; Loo WT; Toi M
J Steroid Biochem Mol Biol; 2011 May; 125(1-2):112-9. PubMed ID: 21236344
[TBL] [Abstract][Full Text] [Related]
7. Effects of sulindac and its metabolites on growth and apoptosis in human mammary epithelial and breast carcinoma cell lines.
Han EK; Arber N; Yamamoto H; Lim JT; Delohery T; Pamukcu R; Piazza GA; Xing WQ; Weinstein IB
Breast Cancer Res Treat; 1998 Apr; 48(3):195-203. PubMed ID: 9598866
[TBL] [Abstract][Full Text] [Related]
8. Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: ALTERNATIVE.
Johnston SRD; Hegg R; Im SA; Park IH; Burdaeva O; Kurteva G; Press MF; Tjulandin S; Iwata H; Simon SD; Kenny S; Sarp S; Izquierdo MA; Williams LS; Gradishar WJ
J Clin Oncol; 2018 Mar; 36(8):741-748. PubMed ID: 29244528
[TBL] [Abstract][Full Text] [Related]
9. Exemestane Use in Postmenopausal Women at High Risk for Invasive Breast Cancer: Evaluating Biomarkers of Efficacy and Safety.
Gatti-Mays ME; Venzon D; Galbo CE; Singer A; Reynolds J; Makariou E; Kallakury B; Heckman-Stoddard BM; Korde L; Isaacs C; Warren R; Gallagher A; Eng-Wong J
Cancer Prev Res (Phila); 2016 Mar; 9(3):225-33. PubMed ID: 26758879
[TBL] [Abstract][Full Text] [Related]
10. Vertebral bone marrow fat fraction changes in postmenopausal women with breast cancer receiving combined aromatase inhibitor and bisphosphonate therapy.
Dieckmeyer M; Ruschke S; Rohrmeier A; Syväri J; Einspieler I; Seifert-Klauss V; Schmidmayr M; Metz S; Kirschke JS; Rummeny EJ; Zimmer C; Karampinos DC; Baum T
BMC Musculoskelet Disord; 2019 Nov; 20(1):515. PubMed ID: 31694630
[TBL] [Abstract][Full Text] [Related]
11. Sulindac and sulindac metabolites in nipple aspirate fluid and effect on drug targets in a phase I trial.
Thompson PA; Hsu CH; Green S; Stopeck AT; Johnson K; Alberts DS; Chow HH
Cancer Prev Res (Phila); 2010 Jan; 3(1):101-7. PubMed ID: 20051377
[TBL] [Abstract][Full Text] [Related]
12. Aromatase inhibitor-induced modulation of breast density: clinical and genetic effects.
Henry NL; Chan HP; Dantzer J; Goswami CP; Li L; Skaar TC; Rae JM; Desta Z; Khouri N; Pinsky R; Oesterreich S; Zhou C; Hadjiiski L; Philips S; Robarge J; Nguyen AT; Storniolo AM; Flockhart DA; Hayes DF; Helvie MA; Stearns V
Br J Cancer; 2013 Oct; 109(9):2331-9. PubMed ID: 24084768
[TBL] [Abstract][Full Text] [Related]
13. Association of Fat Body Mass With Vertebral Fractures in Postmenopausal Women With Early Breast Cancer Undergoing Adjuvant Aromatase Inhibitor Therapy.
Pedersini R; Amoroso V; Maffezzoni F; Gallo F; Turla A; Monteverdi S; Ardine M; Ravanelli M; Vassalli L; Rodella F; Formenti AM; Dalla Volta A; Simoncini EL; Giustina A; Maroldi R; Berruti A
JAMA Netw Open; 2019 Sep; 2(9):e1911080. PubMed ID: 31560383
[TBL] [Abstract][Full Text] [Related]
14. Molecular profiling of aromatase inhibitor-treated postmenopausal breast tumors identifies immune-related correlates of resistance.
Dunbier AK; Ghazoui Z; Anderson H; Salter J; Nerurkar A; Osin P; A'hern R; Miller WR; Smith IE; Dowsett M
Clin Cancer Res; 2013 May; 19(10):2775-86. PubMed ID: 23493347
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of a combined alendronate and calcitriol agent (Maxmarvil®) in Korean postmenopausal women with early breast cancer receiving aromatase inhibitor: a double-blind, randomized, placebo-controlled study.
Rhee Y; Song K; Park S; Park HS; Lim SK; Park BW
Endocr J; 2013; 60(2):167-72. PubMed ID: 23064476
[TBL] [Abstract][Full Text] [Related]
16. Aromatase inhibitors in postmenopausal breast cancer patients.
Rieber AG; Theriault RL
J Natl Compr Canc Netw; 2005 May; 3(3):309-14. PubMed ID: 16002003
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial.
Gnant M; Pfeiler G; Dubsky PC; Hubalek M; Greil R; Jakesz R; Wette V; Balic M; Haslbauer F; Melbinger E; Bjelic-Radisic V; Artner-Matuschek S; Fitzal F; Marth C; Sevelda P; Mlineritsch B; Steger GG; Manfreda D; Exner R; Egle D; Bergh J; Kainberger F; Talbot S; Warner D; Fesl C; Singer CF;
Lancet; 2015 Aug; 386(9992):433-43. PubMed ID: 26040499
[TBL] [Abstract][Full Text] [Related]
18. A prospective, multicenter, controlled, observational study to evaluate the efficacy of a patient support program in improving patients' persistence to adjuvant aromatase inhibitor medication for postmenopausal, early stage breast cancer.
Yu KD; Zhou Y; Liu GY; Li B; He PQ; Zhang HW; Lou LH; Wang XJ; Wang S; Tang JH; Liu YH; Wang X; Jiang ZF; Ma LW; Gu L; Cao MZ; Zhang QY; Wang SM; Su FX; Zheng H; Li HY; Tang LL; Sun SR; Liu JP; Shao ZM; Shen ZZ
Breast Cancer Res Treat; 2012 Jul; 134(1):307-13. PubMed ID: 22527106
[TBL] [Abstract][Full Text] [Related]
19. Impact of chemotherapy on symptoms and symptom clusters in postmenopausal women with breast cancer prior to aromatase inhibitor therapy.
Li H; Sereika SM; Marsland AL; Conley YP; Bender CM
J Clin Nurs; 2019 Dec; 28(23-24):4560-4571. PubMed ID: 31469461
[TBL] [Abstract][Full Text] [Related]
20. Effect of aromatase inhibitors on background parenchymal enhancement and amount of fibroglandular tissue at breast MR imaging.
King V; Goldfarb SB; Brooks JD; Sung JS; Nulsen BF; Jozefara JE; Pike MC; Dickler MN; Morris EA
Radiology; 2012 Sep; 264(3):670-8. PubMed ID: 22771878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]